Avacta Group PLC has announced the release of the abstract of the poster to be presented at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California. The poster presentation will be based on data from the Phase 1a trial of AVA6000, a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by fibroblast activation protein (FAP) in the tumor microenvironment. The presentation will include updated data from the Phase 1 trial beyond those included in the abstract.

The presentation will be titled "A Phase 1 trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors." The session is scheduled for Tuesday, 9 April 2024, at the San Diego Convention Center. The first author of the presentation is Udai Banerji, MD, PhD, from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust.

Following the conference, copies of the poster will be available on Avacta's website, and Christina Coughlin will provide a video presentation overview examining the data presented in the poster. Additionally, Avacta's Chief Executive Officer, Alastair Smith, will host a webinar on 10th April to discuss the data.

AVA6000, Avacta Therapeutics' lead oncology program, is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by fibroblast activation protein (FAP) in the tumor microenvironment. FAP is selectively overexpressed in many solid tumors, and the peptide moiety (pre|CISIONTM) prevents cellular entry of doxorubicin unless cleaved by FAP, enabling targeted delivery of doxorubicin directly to the tumor microenvironment.

Avacta Group is a UK-based company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The company has two divisions: an oncology biotech division developing novel, highly targeted cancer drugs, and a diagnostics division executing an M&A led growth strategy to create a full-spectrum diagnostics business. Avacta's two proprietary platforms, Affimer® and pre|CISION™, underpin its cancer therapeutics, while the diagnostics division leverages the Affimer® platform to drive competitive advantage in its markets.